Amgen Hit Hard as Novartis' Pelacarsen Clinical Trial Fails to Deliver
Novartis has suffered a significant setback in its cardiovascular clinical trial for pelacarsen, developed in collaboration with Ionis Pharmaceuticals. The trial's results have sparked concerns within the pharmaceutical industry regarding the efficacy of Lp(a) targeting drugs.
The lack of meaningful improvement in cardiovascular outcomes from pelacarsen, despite its success in reducing lipoprotein(a) levels, has led analysts to question the Lp(a) hypothesis. This theory suggests that lowering Lp(a) can reduce the risk of heart attacks and strokes.
Amgen Inc., a leader in biotechnology-based human therapeutics, has seen its shares fall by approximately 5% following this news, while Ionis dropped 10%. Amgen's current stock price is $365.80, indicating it is 19.5% overvalued according to GF Value.
Amgen offers a dividend yield of 2.27%, which is relatively attractive in the biotechnology sector. The company has a history of consistent dividend growth and a manageable payout ratio, suggesting that the dividend is sustainable even in the face of market volatility.